GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Middle East Conflict Impacts Australia and New Zealand Businesses 
GAITHERSBURG, Md., May 02, 2018 -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its first quarter 2018 financial and operating results following the close of U.S. financial markets on Wednesday, May 9, 2018.
Conference call details are as follows:
| Date: | May 9, 2018 | |
| Time: | 4:30 p.m. U.S. Eastern Time (ET) | |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) | |
| Passcode: | 3687883 | |
| Webcast: | www.novavax.com, “Investors”/ “Events” |
Conference call and webcast replay:
| Dates: | Starting at 7:30 p.m. ET, May 9, 2018 until | |
| 7:30 p.m. ET May 16, 2018 | ||
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) | |
| Passcode: | 3687883 | |
| Webcast: | www.novavax.com, “Investors”/ “Events”, until August 9, 2017 |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases. Its RSV and influenza nanoparticle vaccine candidates are Novavax’ most advanced clinical programs and are at the forefront of Novavax’ efforts to improve global health. For more information, please visit www.novavax.com.
Contact:
Investors
Erika Trahan
Senior Manager, Investor & Public Relations
[email protected]
240-268-2000
Westwicke Partners
John Woolford
[email protected]
443-213-0506
Media
Sam Brown
Mike Beyer
[email protected]
312-961-2502
